Product Overview
[Drug Name]
Generic Name: Nimodipine Tablets
Trade Name: Huanan Brand
English Name: Nimodipine Tablets
Pinyin: nimodipingpian
[Ingredients]
1,4-Dihydropyridines
[Properties]
Pale yellow tablets, odorless and tasteless. Not very stable to light, but relatively stable to moisture and heat.
[Indications] Calcium antagonist, used for ischemic cerebrovascular disease, migraine, cerebral vasospasm caused by mild subarachnoid hemorrhage, sudden deafness, and mild to moderate hypertension.
[Dosage and Administration]
1. Ischemic cerebrovascular disease: Oral. 30-120 mg daily, divided into three doses, for one month.
2. Migraine: Oral. A 40mg dose three times daily for 12 weeks is effective, with approximately half of cases achieving near-complete or significant recovery. It can reduce pain intensity, frequency, and duration for vascular, tension, cluster, and mixed headaches, and can prevent the onset of premonitory symptoms.
3. Cerebral vasospasm caused by subarachnoid hemorrhage: Oral. 40-60mg three times daily for a three- to four-week course. For patients requiring surgery, discontinue the medication on the day of surgery but continue thereafter.
4. Sudden deafness: Oral. 40-60mg daily, divided into three doses, for a five-day course. Three to four courses are generally required.
5. Mild to moderate hypertension: This medication is preferred for patients with hypertension and cerebrovascular disease. Oral. Initially, 40mg three times daily, with a maximum daily dose of 0.24g. [Adverse Reactions]
Transient gastrointestinal discomfort, dizziness, drowsiness, itchy skin, and flushing. Occasionally, numbness of the lips and rash may occur.
[Contraindications]
Long-term use of antiepileptic drugs such as phenobarbital, phenytoin, and carbamazepine can significantly reduce the bioavailability of oral nimodipine. Therefore, concomitant use of this product with these antiepileptic drugs is not recommended. When used to treat senile brain dysfunction, nimodipine is contraindicated in patients with severe liver dysfunction (such as cirrhosis).
[Precautions]
Use with caution in patients with cerebral edema and increased intracranial pressure. Pregnant and lactating women should follow their doctor's advice. When taking this product, avoid concomitant use with other calcium antagonists or beta-blockers. If concomitant use is necessary, the patient should be carefully observed.
[Use in Special Populations]
Precautions for children: Not yet available.
Precautions for pregnancy and lactation: 1. This drug can be secreted in breast milk; it should not be used by lactating women. 2. Animal studies indicate that this product is teratogenic. Precautions for Elderly: Not yet known.
[Drug Interactions]
Nimodipine is a Ca2+ blocker. Normally, smooth muscle contraction depends on the entry of Ca2+ into the cell, causing a depolarization of the transmembrane current. Nimodipine effectively blocks Ca2+ entry into the cell, inhibiting smooth muscle contraction and thereby relieving vasospasm. Animal studies have shown that nimodipine's effect on cerebral arteries is much stronger than on arteries elsewhere in the body. Due to its high lipophilicity, nimodipine readily crosses the blood-brain barrier. When used to treat subarachnoid hemorrhage, concentrations in cerebrospinal fluid can reach 12.5 ng/ml. This suggests that it could be clinically used to prevent vasospasm after subarachnoid hemorrhage. However, its mechanism of action in humans remains unclear. It also has the potential to protect and promote memory and intellectual recovery. Therefore, it selectively acts on cerebral vascular smooth muscle, dilating cerebral blood vessels and increasing cerebral blood flow, significantly reducing ischemic brain damage caused by vasospasm. [Pharmacological Action]
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. Its pharmacological properties are to effectively regulate intracellular calcium levels, maintaining normal physiological function. Its effects on cerebral blood vessels are particularly pronounced, as it binds to specific receptors in the central nervous system. This specificity makes it effective in preventing and treating ischemic brain damage caused by cerebral vasospasm due to subarachnoid hemorrhage. It inhibits the influx of extracellular calcium ions into vascular smooth muscle cells and dilates cerebral arteries in vitro and in vivo, and in both normal and ischemic cerebral arteries. At appropriate doses, it selectively dilates cerebral blood vessels with minimal impact on peripheral blood vessels. However, increased doses also have a significant effect on hypertension.
[Storage]
Store in a dry, airtight container protected from light.
[Strength]
20mg
[Packaging Size]
20mg*50s/bottle
[Expiry Life]
36 months.
[Approval Number]
National Medicine Standard No. H44025019
[Manufacturer] Company Name: Guangdong Huanan Pharmaceutical Group Co., Ltd.
